TriSalus Life Sciences (TLSI) Operating Expenses (2021 - 2026)

TriSalus Life Sciences' Operating Expenses history runs 6 years deep, the most recent figure standing at $12.9 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 7.38% year-over-year to $12.9 million in Q1 2026; TTM through Mar 2026 was $34.3 million, a 26.39% decrease from a year earlier, with the FY2025 full-year figure at $36.4 million, down 16.85% from the prior year.
• Operating Expenses advanced to $12.9 million in Q1 2026 per TLSI's latest filing, from -$1.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $18.5 million in Q3 2023 and bottomed at -$1.6 million in Q4 2025.
• The 5-year median for Operating Expenses is $10.0 million (2024), against an average of $9.7 million.
• Across the five-year window, Operating Expenses surged 2809.74% in 2023 and tumbled 110.15% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $16.5 million in 2022, then decreased by 16.64% to $13.8 million in 2023, then increased by 14.39% to $15.8 million in 2024, then tumbled by 110.15% to -$1.6 million in 2025, then surged by 904.0% to $12.9 million in 2026.
• Per Business Quant, the three latest TLSI Operating Expenses figures stand at $12.9 million (Q1 2026), -$1.6 million (Q4 2025), and $13.5 million (Q3 2025).